These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
279 related articles for article (PubMed ID: 30573480)
1. Randomised placebo-controlled trial of combination ACE inhibitor and beta-blocker therapy to prevent cardiomyopathy in children with Duchenne muscular dystrophy? (DMD Heart Protection Study): a protocol study. Bourke JP; Watson G; Muntoni F; Spinty S; Roper H; Guglieri M; Speed C; McColl E; Chikermane A; Jayawant S; Adwani S; Willis T; Wilkinson J; Bryant A; Chadwick T; Wood R; Bushby K; BMJ Open; 2018 Dec; 8(12):e022572. PubMed ID: 30573480 [TBL] [Abstract][Full Text] [Related]
2. Interventions for preventing and treating cardiac complications in Duchenne and Becker muscular dystrophy and X-linked dilated cardiomyopathy. Bourke JP; Bueser T; Quinlivan R Cochrane Database Syst Rev; 2018 Oct; 10(10):CD009068. PubMed ID: 30326162 [TBL] [Abstract][Full Text] [Related]
3. Effect and safety of treatment with ACE-inhibitor Enalapril and β-blocker metoprolol on the onset of left ventricular dysfunction in Duchenne muscular dystrophy - a randomized, double-blind, placebo-controlled trial. Dittrich S; Graf E; Trollmann R; Neudorf U; Schara U; Heilmann A; von der Hagen M; Stiller B; Kirschner J; Pozza RD; Müller-Felber W; Weiss K; von Au K; Khalil M; Motz R; Korenke C; Lange M; Wilichowski E; Pattathu J; Ebinger F; Wiechmann N; Schröder R; Orphanet J Rare Dis; 2019 May; 14(1):105. PubMed ID: 31077250 [TBL] [Abstract][Full Text] [Related]
4. Effects of angiotensin-converting enzyme inhibitors and/or beta blockers on the cardiomyopathy in Duchenne muscular dystrophy. Viollet L; Thrush PT; Flanigan KM; Mendell JR; Allen HD Am J Cardiol; 2012 Jul; 110(1):98-102. PubMed ID: 22463839 [TBL] [Abstract][Full Text] [Related]
5. Antioxidants to prevent respiratory decline in people with Duchenne muscular dystrophy and progressive respiratory decline. Garegnani L; Hyland M; Roson Rodriguez P; Escobar Liquitay CM; Franco JV Cochrane Database Syst Rev; 2021 Dec; 12(12):CD013720. PubMed ID: 34850383 [TBL] [Abstract][Full Text] [Related]
6. A systematic review of pharmacologic therapies for the cardiomyopathy of Duchenne muscular dystrophy. Kipke J; Birnkrant DJ; Jin JB; Aneja A; Bahler RC Pediatr Pulmonol; 2021 Apr; 56(4):782-795. PubMed ID: 33621446 [TBL] [Abstract][Full Text] [Related]
7. Cardiac Involvement in Duchenne Muscular Dystrophy and Related Dystrophinopathies. Mavrogeni SI; Markousis-Mavrogenis G; Papavasiliou A; Papadopoulos G; Kolovou G Methods Mol Biol; 2018; 1687():31-42. PubMed ID: 29067654 [TBL] [Abstract][Full Text] [Related]
8. Myocardial Fibrosis Progression in Duchenne and Becker Muscular Dystrophy: A Randomized Clinical Trial. Silva MC; Magalhães TA; Meira ZM; Rassi CH; Andrade AC; Gutierrez PS; Azevedo CF; Gurgel-Giannetti J; Vainzof M; Zatz M; Kalil-Filho R; Rochitte CE JAMA Cardiol; 2017 Feb; 2(2):190-199. PubMed ID: 27926769 [TBL] [Abstract][Full Text] [Related]
9. Left Ventricular Tonic Contraction as a Novel Biomarker of Cardiomyopathy in Duchenne Muscular Dystrophy. Su JA; Ramos-Platt L; Menteer J Pediatr Cardiol; 2016 Apr; 37(4):678-85. PubMed ID: 26714815 [TBL] [Abstract][Full Text] [Related]
10. Beneficial effects of beta-blockers and angiotensin-converting enzyme inhibitors in Duchenne muscular dystrophy. Ogata H; Ishikawa Y; Ishikawa Y; Minami R J Cardiol; 2009 Feb; 53(1):72-8. PubMed ID: 19167641 [TBL] [Abstract][Full Text] [Related]